MorphoSys prelims, guidance

 

• Preliminary 2023 Monjuvi U.S. net product sales of US$ 92.0 million (€ 85.0 million) and preliminary gross margin for Monjuvi U.S. net product sales of 69%
• Anticipated 2024 Monjuvi U.S. net product sales in the range of US$ 80 to 95 million
• Anticipated 2024 OpEx in the range of € 350 to 380 million and 2024 cash burn of approximately € 250 million (excluding debt and interest payments)
• Preliminary unaudited financial liability from the collaboration with Incyte of approximately € 114 million, representing a reduction of € 112 million

https://www.biospace.com/article/releases/morphosys-reports-preliminary-2023-monjuvi-u-s-net-product-sales-and-gross-margin-provides-2024-financial-guidance-and-reduces-financial-liability/